1. Purinergic receptors in the carotid body as a new drug target for controlling hypertension.
- Author
-
Pijacka W, Moraes DJ, Ratcliffe LE, Nightingale AK, Hart EC, da Silva MP, Machado BH, McBryde FD, Abdala AP, Ford AP, and Paton JF
- Subjects
- Animals, Blood Pressure drug effects, Carotid Body cytology, Hypertension drug therapy, Hypertension genetics, Male, Patch-Clamp Techniques, Purinergic P2X Receptor Antagonists pharmacology, Rats, Rats, Inbred SHR, Rats, Wistar, Reflex, Abnormal genetics, Sensory Receptor Cells drug effects, Sensory Receptor Cells metabolism, Blood Pressure genetics, Carotid Body metabolism, Chemoreceptor Cells metabolism, RNA, Messenger metabolism, Receptors, Purinergic P2X3 genetics
- Abstract
In view of the high proportion of individuals with resistance to antihypertensive medication and/or poor compliance or tolerance of this medication, new drugs to treat hypertension are urgently needed. Here we show that peripheral chemoreceptors generate aberrant signaling that contributes to high blood pressure in hypertension. We discovered that purinergic receptor P2X3 (P2rx3, also known as P2x3) mRNA expression is upregulated substantially in chemoreceptive petrosal sensory neurons in rats with hypertension. These neurons generate both tonic drive and hyperreflexia in hypertensive (but not normotensive) rats, and both phenomena are normalized by the blockade of P2X3 receptors. Antagonism of P2X3 receptors also reduces arterial pressure and basal sympathetic activity and normalizes carotid body hyperreflexia in conscious rats with hypertension; no effect was observed in rats without hypertension. We verified P2X3 receptor expression in human carotid bodies and observed hyperactivity of carotid bodies in individuals with hypertension. These data support the identification of the P2X3 receptor as a potential new target for the control of human hypertension.
- Published
- 2016
- Full Text
- View/download PDF